What makes this finding particularly interesting is the fact that previous sequencing studies of the MEK1/2 protein kinase domain failed to identify any mutations in gliomas, testicular germ cell tumors, breast cancer and lung cancer [35]–[38]. Here, MAP2K1 is linked to breast carcinoma.